In this Q&A, Christie Ballantyne, MD, explains why consistent LDL-C lowering with oral enlicitide could expand PCSK9 use in primary prevention. Independent VESALIUS-CV analysis finds evolocumab ...
Revenue was flat at $22.7 million; adjusted EBITDA loss was $6.3 million, and quarter-end cash was $31.7 million as MDxHealth ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results